Artikel

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

Autoimmune Type 1 diabetes (T1D) is undergoing a fundamental transformation in how the medical community approaches diagnosis and care.

PRALUENT: a PCSK9i that ticks all the boxes^1–4 PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.² It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.² Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.¹

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²